APVO
Aptevo Therapeutics Inc.
There isn't enough reported data to score APVO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
APVO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
APVO's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
APVO PE Valuation
APVO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
APVO Forward outlook
There aren't enough analyst estimates for APVO to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
APVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$1,347,984.00 | -280% |
| Q2 2023 | -$1,934,064.00 | -344% |
| Q1 2023 | $2,057,140.80 | +$5,561,899.20 |
| Q4 2022 | $920,145.60 | +$4,477,651.20 |
| Q3 2022 | $750,182.40 | +$4,700,361.60 |
| Q2 2022 | $791,208.00 | +$5,134,060.80 |
| Q1 2022 | -$3,504,758.40 | +$1,043,222.40 |
| Q4 2021 | -$3,557,505.60 | -$492,307.20 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 280% for APVO versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
APVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $3.1M | +29% |
| Q4 2021 | $3.7M | +54% |
| Q3 2021 | $3.1M | +112% |
| Q2 2021 | $3.1M | +558% |
| Q4 2020 | $2.4M | -74% |
| Q3 2020 | $1.5M | -84% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for APVO versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2022 | -180% | +104 points |
| Q4 2021 | -110% | +177 points |
| Q3 2021 | -153% | +274 points |
| Q2 2021 | -184% | N/A |
| Q1 2021 | -285% | N/A |
| Q4 2020 | -287% | -202 points |
| Q3 2020 | -427% | -310 points |
| Q4 2019 | -85% | N/A |
APVO's operating margin was −180% last quarter, up 104 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
APVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.5M | +$1.6M |
| Q1 2026 | -$8M | -$1.4M |
| Q4 2025 | -$5.2M | +$523K |
| Q3 2025 | -$6.7M | -$1.5M |
| Q2 2025 | -$7.1M | -$940K |
| Q1 2025 | -$6.6M | +$76K |
| Q1 2024 | -$6.7M | -246% |
| Q4 2022 | -$5.9M | -$1.9M |
APVO has burned cash in almost every quarter: −$25M over the past year, against −$25M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over APVO on cash generation, producing positive trailing cash flow while its opponent burns cash.
APVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +136K shares |
| 1 year | +29433% | +1.2M shares |
| 3 years | +13292833% | +1.2M shares |
| 5 years | +19939300% | +1.2M shares |
APVO has 1M diluted shares, up 29433% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over APVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
APVO Net Leverage
APVO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
APVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.9 | Oversold |
| Stochastic | 2.8 | Oversold |
APVO's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
APVO PE vs Healthcare Sector
| Metric | APVO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
APVO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
APVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.49 | 56% below |
| 20 week MA | $2.56 | 74% below |
| 50 week MA | $5.60 | 88% below |
| 100 week MA | $233.4 | 100% below |
| 200 week MA | $171,716.8 | 100% below |
APVO is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over APVO on trend strength, trading above more of its moving averages.
APVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4,849,225.9 | $20,747,232.0 | +328% |
| 2021 | $20,747,232.0 | $4,612,449.6 | -78% |
| 2022 | $4,612,449.6 | $1,213,185.6 | -74% |
| 2023 | $1,213,185.6 | $106,080.5 | -91% |
| 2024 | $106,080.5 | $1,731.6 | -98% |
| 2025 | $1,731.6 | $10.9 | -99% |
| 2026 YTD | $10.9 | $0.66 | -94% |
APVO has finished five years in a row lower, and it's down 94% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over APVO on returns for 2026, with the stronger performance.